Intervertebral disc degeneration (IDD), a leading driver of chronic low back pain, has become a major socioeconomic and public health burden due to its high disability rate and substantial treatment costs. Accumulating evidence has redefined IDD as an …
ObjectiveTo analyze and summarize the general patterns and key points of treatment for cytokine release syndrome (CRS) induced by immune checkpoint inhibitors (ICIs), and provide references for the differential diagnosis and treatment of this immune-re…
J Immunol. 2026 Jul 10;215(7):vkag202. doi: 10.1093/jimmun/vkag202. ABSTRACT Effector gene expression in CD8+ T cells is tightly controlled at the epigenetic and transcriptional levels; however, crucial regulatory signals remain incompletely understood. In this study, we identify dual specificity phosphatase 2 (DUSP2) as a key epigenetic modulator of effector CD8+ T-cell state, by elucidating inhibition of … Read more
J Immunol. 2026 Jul 10;215(7):vkag204. doi: 10.1093/jimmun/vkag204. ABSTRACT Natural killer (NK) cells are cytotoxic innate lymphoid cells that play a critical role in tumor surveillance by releasing proinflammatory cytokines and cytotoxic granules. NKp44 is an activating receptor that promotes NK cell secretion of TNF and IFN-γ upon engaging platelet-derived growth factor D (PDGF-DD), a ligand … Read more
J Immunol. 2026 Jul 10;215(7):vkag194. doi: 10.1093/jimmun/vkag194. ABSTRACT The TNF‑like cytokine TL1A is a key regulator of immune responses through engagement of its receptor, death receptor 3 (DR3), and has emerged as a therapeutic target in inflammatory diseases. Prevailing models propose that TL1A binding initiates recruitment of adaptor proteins to DR3, leading to downstream signaling. … Read more
Background
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide and is characterized by an immunosuppressive tumor microenvironment (TME). While adaptive immunity contributes to tumor control, growing evidence underscores t…
Background
Neuroendocrine prostate cancer (NEPC) is characterized by strong immune evasion and profound metabolic reprogramming. A high regulatory T cell (Treg)/CD8+ T cell ratio and an increased proportion of M2/M1 tumor-associated macrophages (TAMs)…
Epithelioid angiomyolipoma (E-AML) is a rare renal tumor, which can exhibit malignant potential. Because angiomyolipomas frequently harbor TSC1/TSC2 alterations, mTOR inhibitors are commonly used. However, durable disease control remains inconsistent….
Background
Although chromosome 14q deletion (14q–) is present in up to 40% of clear cell renal cell carcinoma (ccRCC) cases, its immunologic and molecular impact remains unclear. Because TRAF3 and NFKBIA, key regulators of nuclear factor kappa-l…
Cellular & Molecular Immunology, Published online: 29 July 2026; doi:10.1038/s41423-026-01452-5Tumor cell-released autophagosome (TRAP) programs inflammatory CAFs to drive the immune-excluded TIME through C3a
